Shares of Lanxess climbed about 16% on Wednesday following a double-upgrade from JPMorgan, which moved the stock from Underweight to Overweight and placed it on a Positive Catalyst Watch ahead of the company's first-quarter results scheduled for May 7. The broker also raised its price target to €18 from €15.
In a client note, analyst Chetan Udeshi highlighted the potential for near-term earnings gains tied to ongoing production disruptions in the Asia-Pacific region, which he linked to broader conflict-driven supply interruptions. Udeshi wrote that "Lanxess is best geared to the potential upside in the near term from the ongoing production disruptions in APAC due to ongoing conflict in the Middle East, given its position as one of the very few, if not the only, Western suppliers in its select key product chains."
According to the analyst, the company stands to benefit because disruptions in Asia could ease import-driven competition, supporting both pricing power and volumes that are currently depressed. He specifically noted that in certain product segments - including chlorobenzene and synthetic pigments - Lanxess is the only, or among the very few, Western producers.
Udeshi elaborated on the mechanism: "Given the increasing disruptions in production of these products in APAC due to disruptions to the raw material supply and/or rising production costs, Lanxess should see easing competitive pressure from Asian imports = improving pricing power with better volumes." He cautioned that the magnitude and duration of any earnings upside will depend on how long the APAC disruptions persist and on demand elasticity.
JPMorgan quantified the potential benefit by projecting a meaningful beat to consensus in the near term. The bank's adjusted EBITDA estimate for the second quarter is roughly 43% higher than Bloomberg consensus, and it has lifted its EBITDA forecasts by 15% for 2026 and 13% for 2027. The broker framed those revisions as consistent with a possible end to the recent earnings downgrade cycle for the company.
Beyond external supply dynamics, internal cost measures also factored into JPMorgan's assessment. Lanxess is targeting around €150 million in incremental savings between 2026 and 2028. Udeshi indicated those savings should largely offset fixed-cost inflation and boost earnings leverage as volumes recover.
While JPMorgan pointed to significant near-term upside, the analyst noted remaining balance sheet concerns. He suggested, however, that stronger-than-expected earnings in the near term could provide additional flexibility to deleverage the balance sheet.
Summary of developments - JPMorgan upgraded Lanxess to Overweight from Underweight, raised its price target to €18, put the stock on Positive Catalyst Watch ahead of May 7 Q1 results, and cited APAC production disruptions and planned cost savings as key drivers for potential earnings upside.